Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$390K
Filings
24
Firms Hired
3
Active Period
2022–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 3832
Preparing for All Hazards and Pathogens Reauthorization Act
2023 · fourth_quarter · Firm: INVIVYD, INC.
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: — · Firm income: $70,000
Matched citations: H.R.4421
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 3832
Preparing for All Hazards and Pathogens Reauthorization Act
2023 · third_quarter · Firm: INVIVYD, INC.
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: — · Firm income: $70,000
Matched citations: H.R.4421
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 3832
Preparing for All Hazards and Pathogens Reauthorization Act
2023 · second_quarter · Firm: INVIVYD, INC.
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Client expense: — · Firm income: $70,000
Matched citations: H.R.4421
Source: Senate LDA